CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Tecentriq for Small Cell Lung Cancer – Details

Project Number PC0156-000
Brand Name Tecentriq
Generic Name Atezolizumab
Strength 60 mg/mL
Tumour Type Lung
Indication Small Cell Lung Cancer (SCLC)
Funding Request For the first-line treatment of patients with extensive stage small cell lung cancer (ES-SCLC) in combination with a platinum-based chemotherapy and etoposide. Maintenance TECENTRIQ should be continued until loss of clinical benefit or unacceptable toxicity
Review Status Notification to Implement Issued
Clarification A procedural review request has been received and granted.
Pre Noc Submission Yes
NOC Date August 8, 2019
Manufacturer Hoffmann-La Roche Limited
Sponsor Hoffmann-La Roche Limited
Submission Date March 4, 2019
Submission Deemed Complete March 18, 2019
Submission Type Initial
Prioritization Requested
Stakeholder Input Deadline ‡ March 18, 2019
Check-point meeting May 7, 2019
pERC Meeting September 19, 2019
Initial Recommendation Issued October 3, 2019
Feedback Deadline ‡ October 18, 2019
pERC Reconsideration Meeting November 21, 2019
Final Recommendation Issued January 30, 2020
Notification to Implement Issued February 14, 2020
Therapeutic Area Small Cell Lung Cancer (SCLC)
Recommendation Type Do not reimburse

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.